Trial Profile

Phase I/II trial of EG 011 in patients with angina pectoris.

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 21 May 2012

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs EG 011 (Primary)
Indications Angina pectoris
Focus Therapeutic Use
Sponsors Ark Therapeutics

Most Recent Events

16 May 2012 The phase I dose-ranging component of the trial has completed enrolment; enrolment in the phase IIa stage of the trial is expected to begin in the third quarter of 2012 according to an Ark Therapeutics media release.
18 May 2011 Recruitment into the low-dose group has been completed and several patients have been treated with the high dose, according to an Ark Therapeutics media release.
28 Jan 2010 The first patient has been enrolled and treated according to an Ark Therapeutics media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com